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Autophagy1 is a complex of adaptive cellular response that enhances cancer cell survival in the face of cellular
stresses such as chemothery. Here we show that in human gallbladder carcinoma (GBC) cells lines, SGC-996 and
GBC-SD, autophagy is induced by the DNA damaging agent 5-fluorouracil (5-FU). While in combination with the
pre-treatment of chloroquine (CQ), a inhibitor of autophagy, the inhibition of 5-FU to the proliferation and viability
of GBC cells was potentiated. Furthermore, 5-FU treatment resulted in a general increase of the apoptotic rate and
G0/G1 arrest of GBC cells, and the effect was potentiated by CQ pre-treatment. Since 5-FU induced autophagy in
GBC cells, and CQ inhibited autophagy, our findings suggest a possible mechanism that CQ inhibited 5-FU-induced
autophagy, which modified the cytotoxicity of 5-FU. The combination therapy of CQ and 5-FU should be
considered as an effective strategy for the treatment of gallbladder carcinoma.Introduction
To improve cancer cure rates, understanding of the
mechanisms of the anticancer agents, as well as the
mechanisms of acquisition of chemoresistance by cancer
cells, is essential. Primary gallbladder carcinoma is one
of the most common malignancies of the digestive tract
in china and has been increasing incidence worldwide
[1]. There is no specific symptom for such patients. In
the majority of cases, the diagnosis of this carcinoma is
usually made postoperatively on tumors at an advanced
stage, resulting in a 5-year survival rate of <10% and al-
most half of patients already have metastatic disease at
the time of surgery [2,3]. So far as we know, there are
no adjuvant chemotherapeutic combinations widely ac-
cepted for the primary gallbladder carcinoma due to
their toxicity, drug resistance and limited efficacy. One
approach to overcome this major problem may be the
discovery of new therapeutic applications for already
existing drugs, which is termed ‘repurposing’ [4].
CQ, a widely used antimalaria drug, has been used for six
decades as its effectiveness, low price, low toxicity to
humans and well understood pharmacological properties* Correspondence: cxjzu@hotmail.com
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unless otherwise stated.[5,6]. CQ is also a choice for treatment of diverse diseases
such as rheumatoid arthritis, lupus erythematosus and
amoebic hepatitis [7,8]. More recently, importance has been
attached to the ability of CQ to block autophagy by inhi-
biting lysosomal proteases and autophagosome-lysosomal
fusion events [9]. Since autophagy is thought to act as a
cell-survival pathway in cancer [10,11], CQ has been stud-
ied as a potential agent in cancer therapy. It’s notably that
combing CQ with the DNA alkylating agent cyclophos-
phamide significantly increased the rate of tumor regres-
sion and delayed tumor recurrence [12]. Up to now, CQ
and its derivatives are the only inhibitors of autophagy
available for clinical treatment of patients. There are more
than twenty clinical trials listed on the clinicaltrials.gov
website [13] using CQ or its derivatives to test if inhibition
of autophagy in a clinical setting can increase the effect-
iveness of cancer therapies [14].
Autophagy is a highly conserved survival response to
growth limiting conditions, such as nutrient depletion,
hypoxia and the presence of cytotoxic drugs [15,16].
It is genetically regulated by a family of autophagy-
related (ATG) genes and can be detected by molecularly
antibody-based detection of gene, microtubule-associated
protein 1 light chain 3 (LC3). LC3 is constitutively
expressed at low levels in most cells, and conjugatedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Liang et al. Cell & Bioscience 2014, 4:10 Page 2 of 11
http://www.cellandbioscience.com/content/4/1/10with phosphatidylethanolamine targets the autophago-
somal membrane. The conjugated form of LC3 is
called LC3-II and regarded as specific marker of au-
tophagy [17]. Meanwhile, recent studies indicate the
p62 protein function as an adaptor molecule involved
in activating autophagy that interacts with polyubiqui-
tinated protein aggregates and targets them to autop-
hagosomes [18].
In the present study, we aimed to investigate the ef-
fects of the combination of chemotherapy with CQ on
two kinds of gallbladder-carcinoma-derived cells, namely
SGC-996 and GBC-SD. 5-FU is one of the major antitu-
mor agents widely used against cancer for about 40 years.
It exerts its anticancer effects through the inhibition of
thymidylate synthase and the incorporation of its active
metabolites, into RNA and DNA so as to influence the
uracil metabolism and has been used in Phase II trial of
combination chemotherapy for advanced cancers of the
gallbladder [19,20]. Our research reveals the chemo-
sensitizer of CQ on 5-FU may be partly dependent
on its ability to inhibit autophagy. Moreover, 5-FU-
induced apoptosis was enhanced after the inhibition
of autophagy, suggesting a novel and promising strat-
egy to increase the clinical efficacy of 5-FU for the
treatment of gallbladder carcinoma.
Materials and methods
Reagents and antibodies
5-FU, CQ and bovine serum albumin (BSA) were pur-
chased from Sigma-Aldrich. RPMI-1640, DMEM medium
and fetal bovine serum (FBS) were from Gibco. Primary
antibodies against LC3, GAPDH were from Cell Signaling
Technology, Inc. Primary antibodies against P62, Atg5,
Atg7 were from Epitomics, Inc. The GFP-LC3 plasmid was
a gift from Dr. Hong-Chuan Jin’s lab at Zhejiang University,
China.
Cell cultures and transfection
Human gallbladder carcinoma cell line GBC-SD was
bought from cell bank (Chinese Academy of Sciences).
Each respectively, SGC-996 or GBC-SD cells was main-
tained in RPMI-1640 or DMEM supplemented with 10%
(v/v) FBS and 1% (v/v) penicillin/streptomycin and incu-
bated in a humidified 5% CO2 incubator at 37°C. The
plasmids (GFP-LC3) or small interfering RNA (siRNA;
Atg5 and Atg7) were transiently transfected into cells
with Lipofectamine 2000 transfection or RNAi MAX
reagent according to the manufacturer’s instructions
(Invitrogen). After 24 hours, the cells were treated with
5-FU or CQ and subjected to fluorescent analysis or
Western blotting assay. The SGC-996 cell line was
provided by Dr. Ying-Bin Liu’s lab at Xin Hua Hospital
Affiliated to Shanghai Jiao Tong University School of
Medicine, China.FU and CQ treatment
Two human GBC cells were seeded and grown until they
reached about 40-50% subconfluence. And then the cells
were pre-treated with CQ for 12 hours, after washing with
PBS the cells were treated with or without 5-FU for 48 h.
The treatment was washed and replaced with regular
media. Since 100 μM CQ mostly induced the formation of
Acidic vesicular organelles (AVOs) while did minimal in-
hibition on GBC cells in 12 hours, in the subsequent exper-
iments, the dose of CQ was set at 100 μM, followed by
washing with PBS and then treated with 5-FU (5 μM) for
another 24-48 h.
Cytotoxicity assay
The cytotoxicity of chemicals against SGC-996 and GBC-
SD cells was determined by CCK-8 assay. Cells were seeded
into 96-well plates and treated with chemicals with different
concentrations. After 24 h or 48 h incubation, 20 μl CCK-8
was added into each well for 4 h incubation. The absorb-
ance was then measured using a model ELX800 Micro
Plate Reader (Bio-Tek Instruments, Inc.) at 450 nm.
Detection of acidic vesicular organelles (AVOs)
Cells undergoing autophagy generally develop double-
membraned, acidic vesicular organelles (predominantly of
autophagosomes and autolysosomes), which can be de-
tected by specific dyes. Acridine orange (AO) is a fluores-
cent emit green light when it bounds to DNA, while it
accumulates in acidic spaces and fluoresce bright red. It
selectively recognize autophagosomes and autolysosomes,
and the intensity of the red fluorescence is proportional to
the degree of acidity, also represents AVOs formation [21].
SGC-996 and GBC-SD cells were prepared and treated
as described, and the cells were resuspended in PBS
(−) and stained with AO (5 μg/ml) for 15 min at room
temperature. The cells were examined under a fluores-
cence microscope at 40 × objective lens magnification.
Cell mortality analysis
1 × 105 cells were prepared and treated as described, col-
lected by trpsinization, centrifuged, resuspended in 500 μl
PBS and stained with 0.5% trypan blue. The unstained
cells were quantified using a counting chamber.
Apoptosis detection
1 × 105 cells were prepared and treated as described,
collected by trpsinization, centrifuged, washed twice
with 3 ml PBS, resuspended in 500 μl PBS and stained
with 1% Annexin V-FITC/PI, analyzed by FACS caliber
(Becton Dickinson).
Cell cycle analysis
1 × 105 cells were prepared and treated as described.
After serum starved starvation and treatment, cells
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fuged, resuspended in 1 ml PBS and fixed with 80%
methanol to obtain a final concentration of 70%-75%.
The fixed cells were stored in a −20°C at least for
12 h. Before analysis, cells were washed once withFigure 1 CQ increased the expression of LC-3 and p62 in GBC cells af
following treatment of GBC cells with 5-FU for 24 hours or 48 h by western
from the bands of the western blot (*, p < 0.05 vs. control, n = 3). (B) Repre
left), 5-FU-treated (5 μM) for 24 hours (upper middle) or 48 hours (upper le
higher magnification (lower), with typical double-layer membrane containin
untreated cells. (C) Western blot analysis of LC-II and p62 from lysates of G
pre-treatment with CQ. GAPDH was used as a loading control and the exp
(*,p < 0.05 vs. control, n = 3). (D) SGC-996 cells were transfected with vecto
100 μM CQ and/or 5 μM 5-FU as described. The GFP or GFP-LC3 staining p
cells display diffuse GFP distributed throughout the cytoplasm, coincident
panels). Both 5-FU and CQ (lower middle panels) induced punctuate patte
5-FU combined with CQ (lower right panels) showed a similar diffuse GFP-
of at least three independent experiments and quantification of green dot3 ml PBS, resuspended in 250 μl PBS containing 1%
RNase and 1% propidium iodide. After incubation in
dark for 30 minutes, treated cells were analyzed by
FACS caliber and the obtained results were analyzed
by the Cell Quest software.ter treatment with 5-FU. (A) Time course detection of LC-II and p62
blot. The lower panels represent the densitometric values obtained
sentative electron microscopy images of control SGC-996 cells (upper
ft). Obvious autophagic vacuoles were highlighted by white arrows in
g organelle remnants present in 5-FU treated cells rather than
BC cells treated with 5-FU alone for 48 h or after 12 hours
ressions of autophagy-related proteins (LC3-II, p62) were quantified
rs expressing either GFP or GFP-LC3, followed by pre-treatment of
atterns were analyzed by fluorescence microscopy. The GFP control
with GFP-LC3 patterns of SGC-996 vehicle control cells (lower left
rns in GFP-LC3 patterns, while the latter was more bright and clear.
LC3 but notably bright punctuate patterns. Images are representative
s is shown in graph as mean ± SD (*,p < 0.05, n = 5, Scale bar = 10 μm).
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SGC-996 cells, suspended in fresh culture medium,
were plated 500 cells/well onto 35 mm Dish. The via-
bility cells were allowed to attach in 24 hours and
treated with CQ at 100 μM for 12 hours, washed with
PBS, and/or treated by 5-FU at 5 μM for 48 hours. Then,
cells were washed with PBS (−), and fed with fresh
culture medium, without CQ and/or 5-FU, and allowed
to grow for 14 days in normal culture conditions (37°C,
5% CO2). To visualize colonies contained 50 or more
cells during the 14 days of culture, media was re-
moved, cells were fixed in 3.7% paraformaldehyde for
15 min and stained with crystal violet and the col-
onies were counted under light microscope. For each
experimental condition, colonies were presented as
the mean number ± SD from at least 3 independent
experiments were counted.Figure 2 Effect of CQ in 5-FU-induced GBC cell proliferation and mort
of 5-FU on the proliferative activity and cell mortality rate of SGC-996 cells
exclusion staining. The y-axis represents the proliferation/mortality rate, calc
given as mean ± SD. (A) Pre-treatment of cells with CQ at 100 μM for 12 h
significantly potentiation of the inhibitory effect (25% vs. 62% inhibition (SG
and CQ + 5-FU, respectively) (*,p < 0.05 vs. control, n = 5). (B) When cells we
at 5 μM for 48 hours, the mortality rate reduction was notably potentiated
(GBC-SD cells) for 5-FU alone and CQ + 5-FU , respectively) (*,p < 0.05 vs. coProtein isolation and western blots analysis
After treatment, cells were washed with PBS and lysed with
RIPA buffer with protease inhibitors. Protein was quanti-
tated using BCA protein assay (Pierce). 10–30 mg of total
protein were resolved by SDS-polyacrylamide gel electro-
phoresis, transferred to a PVDF membrane (Millipore) and
then detected by the proper primary and secondary anti-
bodies before visualization with a chemiluminescence kit
(Pierce). The visualization was done with Image Quant
LAS-4000 (Fujifilm, Tokyo, Japan).
Fluorescence microscopy
Cells were transfected with GFP-LC3 plasmids, followed
by treatment as described. The cells were then rapidly
washed with PBS and fixed at room temperature for
15 minutes with 3.7% paraformaldehyde. After being
washed with PBS twice, cell nuclei were stained byality inhibition. The effect of CQ-pretreatment on the inhibitory effect
and GBC-SD cells was investigated by CCK-8 assay and trypan blue
ulated as the ratio to normal control (untreated cells). Values were
ours prior to exposure to 5-FU at 5 μM for 48 hours, resulted in
C-996 cells) and 24% vs. 50% inhibition (GBC-SD cells) for 5-FU alone
re treated with CQ at 100 μM for 12 hours prior to exposure to 5-FU
(60% vs. 28% live cells (SGC-996 cells) and 67% vs. 21% live cells
ntrol, n = 5).
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microscope.
Transmission electron microscopy
Treated cells were washed and fixed for 30 min in 2.5%
glutaraldehyde. The sample were post-fixed in 1.5% os-
mium terroxide, dehydrated in ascending grades of etha-
nol solutions (50%, 70%, 90%, 100%) and acetone, prior to
embedding in araldite resin. Thin sections were prepared
on an ultramicrotome and stained with uranyl acetate and
wolfberry lead acid. All sections were examined and
photographed with a Philips TECNAI 10 electron micro-
scope at 80 kV.
Statistical analysis
Unless otherwise stated, data was expressed as the mean ±
SD and analyzed by Student’s t test, differences were con-
sidered significant when the P value was less than 0.05.
Results
Effect of 5-FU and CQ on the proliferative activity of GBC cells
The CCK-8 assay revealed CQ show a weak cytotoxic effect
at the dose of 100 μM for 12 hours while the cytotoxicityFigure 3 CQ enhanced the cytotoxicity of 5-FU through inhibiting aut
cells after treatment with 5-FU was examined by ATG5 and ATG7 with siRN
siRNA treatment (upper), in parallel with the protein levels after the transfe
transiently transfected with negative control siRNA, Atg-5 or Atg-7 siRNA w
mortality rates were measured by CCk-8 assay and the trypan blue exclusiowas significantly increased by 24 h-treatment of the same
concentration (Additional file 1: Figure S1A). On the other
hand, 100 μM CQ mostly induced the formation of AVOs
equal to the dose of 200 μM (Additional file 1: Figure S1B),
with minimal inhibition on GBC cells at the same time. Ac-
cording to above results, the concentration of 100 μM of
CQ in 12 h-treatment which show slight inhibition on
GBC cells were selected for the further experiments.
CQ blocked autophagy induced by 5-FU in GBC cells
In order to investigate the effect of 5-FU on autophagy
as well as the inhibitory effect of CQ, the expression of
LC3-II and p62 in GBC cells was investigated by
Western blot (Additional file 2: Figure S2). Since earlier
reports have demonstrated that the antitumor effects of
5-FU depend on exposure duration rather than plasma
concentration levels [22], the time course following
treatment of GBC cells with 5-FU alone was conducted.
The results revealed a time-dependent changes of the au-
tophagic markers, including accumulation of LC3-II and
degradation of p62 (Figure 1A). More importantly, CQ
pre-treatment markedly increased both LC3-II and p62
protein levels, indicating the enhanced autophagic fluxophagy. (A) The contribution of autophagy to SGC-996 and GBC-SD
A. The mRNA expression of each gene were significantly reduced by
ction (lower). GAPDH was used as a loading control. (B) GBC cells
ere treated with 5 μM 5-FU for 48 hours. Cell proliferation and
n staining (*,p < 0.05 vs. control, n = 3).
Figure 4 (See legend on next page.)
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Figure 4 CQ potentiates apoptosis of SGC cells induced by 5-FU. (A) The population of annexin V+ apoptotic cells were evaluated by FCM
using annexin V-FITC/PI staining in SGC-996 cells and GBC-SD cells after CQ-pretreatment at 100 μM for 12 hours, followed by 5-FU at 5 μM for
48 hours. The percentage of annexin V+ apoptotic cells increased by pretreatment with CQ followed by 5-FU. Values were given as mean ± SD.
(B) GBC cells were treated with CQ at 100 μM for 12 hours, washed with PBS, and/or treated by 5-FU at 5 μM for 48 hours respectively. GAPDH
was used as an internal control. Cleavage of PARP induced by 5-FU and CQ in GBC cells was examined with Western Blotting analysis. The values
of the band intensity below the figure represent the densitometric estimation of each band normalized by GAPDH. Experiments were repeated
three times with reproducible results.
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the ultrastructural features of SGC-996 cells, following
24-h or 48-h treatment with 5-FU (5 μM), revealed mor-
phological changes including obvious autophagic vacu-
oles in the cytoplasm compared with cells in basal state
(Figure 1B).
Moreover, green fluorescence showed mostly a uni-
form distribution in untreated GFP-LC3 expressing
SGC-996 cells. Coincidentally, a few green dots were ob-
served under 5-FU treatment conditions and punctuate
patterns of GFP-LC3 representing autophagic vacuoles
were formed in the cytoplasm after treatment of 5-FU
combined with CQ (Figure 1D). These results showed
that 5-FU induced the autophagy activation and autoph-
agy process occurred within several hours after treat-
ment with drug.CQ potentiated the suppression of the growth in GBC
cells induced by 5-FU
Our studies demonstrated that 5-FU inhibited the prolifera-
tion of GBC cells in time- and dose-dependent maner.
Meanwhile, a single dose of 5-FU at 5 μM was required to
reduce around 30% proliferative rate in GBC cells accord-
ing our experiments and below the maximum concentra-
tion to cause the myelotoxicity. After a pre-treatment of
100 μM CQ for 12 hours, which had nearly no inhibitory
effect on GBC cells, notably potentiated over 50% suppress
proliferation effect of 5 μM 5-FU treatment for 48 hours
(Figure 2A). Similar to the results of cell mortality analysis,
the growth of GBC cells were significantly decreased by
combination treatment of CQ and 5-FU, in comparison
with the 5-FU or CQ alone (Figure 2B).CQ enhanced the cytotoxicity of 5-FU through inhibiting
autophagy
Since autophagy is a mechanism to promote or delay cell
death [23], we assessed whether inhibition of autophagy
contributed to the enhanced cytotoxicity of 5-FU when
combined with CQ. Moreover, we also found 3-MA
(a well-know autophagy inhibitor) potentiated the sup-
pression of the growth in GBC cells induced by 5-FU (data
not show). It’s supposed the resistance of GBC cells to
5-FU may be overcome with autophagy inhibitor.Two key regulators of autophagy, ATG5 and ATG7
with short interfering RNA (siRNA) were designed to
examine the contribution of autophagy to survival and
recovery of GBC cells after the treatment of 5-FU. The
levels of knockdown achieved for each gene mRNA
and protein expression, were mostly great than 80%
at 72 hours (Figure 3A). 24 hours after addition of siRNA,
cells were treated with 5 μM 5-FU for 48 hours. The ad-
herent cells were collected, stained with trypan blue and
counted (Figure 3B). These cells counts indicated that
knockdown of ATG5 or ATG7 reduced the proliferation
and mortality at 48 h post treatment with 5-FU at concen-
tration of 5 μM. Taken together, these data suggest that
as the specific inhibitor, CQ enchanced the cytotoxicity of
5-FU by inhibiting autophagy.
CQ increased apoptosis and potentiated the G0/G1 arrest
of GBC cells induced by 5-FU
In clarify whether the inhibitory effect of 5-FU combined
with CQ on GBC cells was due to apoptosis and/or cell
growth arrest, flow cytometry and colony formation
assay were used. CQ pre-treatment resulted increasing
of the percentage of apoptotic cells followed by 5-FU
treatment (34.3% compared to 46.2% for treated with
5-FU alone and CQ+ 5-FU in GBC-SD cells, 23.4% com-
pared to 48.6% for 5-FU alone and CQ + 5-FU in SGC-
996 cells, respectively) (Figure 4A). Consistently, the level
of cleaved product of caspases substract Poly ADP-ribose
Polyermerase (PARP) was correlated with the activation of
caspases (Figure 4B).
Moreover, pre-treatment with CQ resulted in incre-
ment of the percentage of GBC cells at the G0/G1 phase,
compared with the cells treated with 5-FU alone (52.7%
compared to 74.6% for 5-FU alone and CQ + 5-FU in
SGC-996 cells, 61.6% compared to 76.8% for treated
with 5-FU alone and CQ + 5-FU in GBC-SD cells, re-
spectively) (Figure 5A). The viability of the GBC cells
after treatment with 5-FU and/or CQ was assessed by
the colony formation assay. Cell were pre-treated with
or without CQ for 12 hours followed by 5-FU treatment
for 48 hours, and then fed with fresh complete culture
medium for 2 weeks. Single treatment of 5-FU or CQ
caused a delay and slight inhibition of the colony forma-
tion, whereas pre-treatment of cells with CQ at 100 μM
Figure 5 (See legend on next page.)
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Figure 5 CQ inhibited the colony formation of GBC cells combined with 5-FU. (A) The analysis of changes in cell cycle was quantified by
flow-cytometry after PI staining in SGC-996 cells and GBC-SD cells treated without or with 5-FU for 48 h after 12 hours pre-treatment without or
with CQ. Values were given as mean ± SD. Treatment of GBC cells with 5-FU alone resulted in increased intra-S arrest, but the G1 arrest was
potentiated by CQ-pretreatment. Meanwhile, G2/M progression of GBC cells was blocked by the treatment with 5-FU alone, and it was
potentiated by the 12 hours pretreatment of CQ. (B) The colony formation assay was used to assess recovery GBC cells treated without or with
5-FU for 48 h after 12-h pretreatment without or with CQ (100 μM). Values were given as mean ± SD. Single treatment of 5-FU or CQ alone
resulted in a delay and slight inhibition of the colony-forming ability, at day 13 of culture most cells were recovery and had formed colonies.
However, pre-treatment of cells with CQ prior to exposure to 5-FU resulted in enhanced inhibitory effect on the colony forming ability, which
was recovery lower than 50% of control untreated cells at day 13 (*, p < 0.05 vs. control, n = 3).
Liang et al. Cell & Bioscience 2014, 4:10 Page 9 of 11
http://www.cellandbioscience.com/content/4/1/10for 12 hours prior to 5-FU significantly reduced colony
formation (Figure 5B).
Discussion
To our best knowledge, it is the first report to show the
potential applicability of CQ to improve the cytotoxicity
of 5-FU in SGC-996 and GBC-SD cells. The aim of the
research is to investigate the effect of 5-FU on human
gallbladder carcinoma cells by CQ, the well-known lyso-
somotropic agent and the inhibitor of autophagy.
Since previous studies have demonstrated that CQ
does cytotoxic effects to certain cancer cell [24,25], we
determined the dose of CQ to mostly inhibit the autoph-
agy without a direct cytotoxic effect on GBC cells. Previ-
ous studies have indicated that the biological effect of
CQ is concentration-dependent. When the concentra-
tion increasing, CQ inhibits cell growth and induces
vacuolation with acidic compartments. At higher con-
centrations, or over longer periods, CQ directly induces
apoptosis and necrosis. In this study, CQ showed a weak
cytotoxic effect at the dose of 100 μM for 12 hours, the
proliferation rate in such condition is about 95% com-
pared to the normal control. Therefore, the dose we
used for this research did not have a direct cytotoxic ef-
fect on GBC cells.
Among the chemotherapeutic agents used against
cancer, 5-FU remains the popular one. The molecular
mechanisms of 5-Fu-induced autophagy activation are
complicated. In colon cancer cell, autophagy takes
part in the response to 5-FU through the regulation of
Bcl-xL protein [26], it appears to be a link between
autophagy and the apoptosis pathways. On the other
hand, p53-AMPK-mTOR may participate in 5-FU-
induced autophagy response as well [27]. Here we
showed that combinational treatment of CQ and
5-FU had better efficacy in killing GBC cells. Differing
from other inhibitors of autophagy, CQ inhibit autophagy
at the time of autophagosomes have already been formed,
we observed CQ accumulated AVOs in a concentration-
dependent maner. Besides, the expression of LC3-II is
time- and dose-dependent as well, which was in par-
allel with the results of AVOs, indicating CQ blocked
the degradation of autophagic vesicles and thereforethe completion of autophagy. The treatment of GBC
cells with combination of CQ and 5-FU resulted in
potentiation of the inhibitory effect on the prolifera-
tion, viability and increasing rate of apoptotic cells as
well. The colony formation assay was conducted to assess
the morphologically distinction between the cells treated
with CQ and/or 5-FU, single treatment of 5-FU or CQ
alone resulted in a delay and partially inhibition on
colony-forming ability, suggest that autophagy is a mech-
anism necessary for cell survival under such conditions,
and result GBC cells to a temporary quiescent state which
probably dependent on the cell arrest to G0/G1 phase.
While the combination of CQ pre-treatment and 5-FU
significantly inhibited the colony-forming ability of GBC
cells, and was not restore after 13 days in normal culture.
Our results are consistent with other reports that au-
tophagy inhibition by CQ or other autophagy inhibitor
(e.g., ATG-5 siRNA and ATG-7 siRNA) induces cell death
in cancer cell types [28-34].
Treatment of the GBC cells with 5-FU results the
increase of LC3-II and decrease of p62 expression com-
pared with the control untreated cells, which was time-
dependent. While it’s convinced that autophagy can be
inhibited by CQ, we hypothesized that GBC cells induced
autophagy as the defense mechanism against 5-FU, and
the inhibition of autophagy treated by CQ could be re-
sponsible for the potentiation of the cytotoxicity of 5-FU.
The siRNAs specific to human Atg5 and Atg7 were used
to block the autophagy at a proximal step as ATGs are es-
sential to the formation of the Atg-Atg12 complex to acti-
vate autophagy. We examined the proliferation and
mortality rates of the GBC cells treated with siRNA and/
or 5-FU, the results of siRNA-mediated knockdown assays
revealed a lack of the ability of autophagy can significantly
enhance the efficacy of 5-FU on GBC cells and provided
an opportunity for human gallbladder carcinoma.
Recently, autophagy has been shown to play a role as
self-defense mechanism in promoting tumor cell resist-
ance to the chemotherapy. Howerver, the mechanism
remains debated. In this study, we demonstrated that au-
tophagy may contribute to chemoresistance in GBC cells,
since pre-treatment of CQ increased the 5-FU-induced
apoptosis and the G0/G1 arrest in vitro. The relationship
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some case they had no connection [35,36] while some report
demonstrated autophagy might promote or even restrain
apoptosis [37,38]. At the molecular level, the interaction
between them is manifested by numerous genes including
Atg5, the Bcl-2 family, p53, ARF, DAPk, and E2F1 [39-42].
The crosstalk between apoptosis and autophagy is a key
factor in the outcome of cancer [42] while how autophagy
helps tumor cells resist to apoptosis remains poorly
defined. Similarly, we also observed inhibition of autoph-
agy enchanced 5-FU-induced cell growth. Since pre-treat-
ment with CQ resulted in increment of the percentage of
GBC cells at the G0/G1 phase in our present study, it is
possible that cell cycle influences autophagic degradation,
and inhibition of autophagy may lead cells to be arrested
to the G0/G1-phase. While the exact mechanism for inhib-
ition of autophagy increase the cytotoxicity of 5-FU in
GBC cells deserved to be verified.
In summary, here we report, for the first time, that
5-FU induced cytotoxicity can be potentiated by CQ pre-
treatment. Since we showed that blocking of autophagy
by genetic (ATG5 siRNA and ATG7 siRNA) or pharma-
cological (CQ) means induced cell death in GBC cells
grown with 5-FU, it’s possible that autophagy plays a pro-
tective role in proteasome inhibitor-induced cell death by
elimination cytotoxic cellular component, it may be an re-
sistant factor which diminishes therapeutic effect in both
sensitivities and resistantance of gallbladder carcinoma.
We therefore propose that blocking autophagy simultan-
eously can overcome resistance of GBC cells to 5-FU-
induced cell death. Further study, for example, in pre-
clinical trial using animal models of gallbladder carcinoma
is required to test the efficacy and efficiency of CQ and
5-FU in vivo.Additional files
Additional file 1: Figure S1. Effect of CQ and 5-FU on the proliferative
and growth activity of GBC cells. (A) The cell proliferative and growth
activity of CQ-treated SGC-996 cells and GBC-SD cells for 12 and 24 hours
were assessed by the CCK-8 assay and the trypan blue exclusion staining.
The y-axis represents the proliferation rate or viability, calculated as the
ratio to normal control (untreated cells). CQ treatment at 100 μM for
24 hours resulted in significant inhibition of the proliferative activity of
SGC-996 cells and GBC-SD cells comparing to the 12 hours treatment, but
not at lower doses (*, p < 0.05, n = 3) (B) The cell proliferative and growth
activity of 5-FU-treated SGC-996 cells and GBC-SD cells for 24 and
48 hours were assessed by the CCK-8 assay and the trypan blue exclusion
staining. The y-axis represents the proliferation rate or viability, calculated
as the ratio to normal control (untreated cells) (*, p < 0.05, n = 3). (C) CQ
induced the formation of AVOs of GBC cells. The formation of AVOs
(proportional to the intensity of red stain) was obtained with the
fluorescence microscopic examination, confirming the autophagy
induced by vary doses of CQ (0, 10, 50, 100, 200 μM).
Additional file 2: Figure S2. Starvations treatment increased the
expression of LC-3 in GBC cells. GBC cells were cultured in Earl’s balanced
salt solution (EBSS; Gibco® 14155–063) for 3 hours to activate starvation-
induced autophagy. Lysates were then prepared and analyzed byimmunoblotting using antibodies against various proteins. GAPDH was
used as a loading control and both LC3-II/LC3-I and LC-3II/GAPDH
densitometric ratios were marked. (*,p < 0.05 vs. control, n = 3).
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